Global Alzheimer’s Disease Drug Biomarkers Insight 2028 Report Highlights.
Global Alzheimer’s Disease Drug Biomarkers Insight 2028 Report Highlights:
- Global Alzheimer’s Disease Antibodies Market Opportunity: > USD 5 Billion
- Alzheimer’s Disease Clinical Trials Insight: > 200 Drugs In Trials
- Alzheimer’s Disease Biomarkers Sourced During Clinical Trials
- Alzheimer’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report Sample:
http://biomarkersinsights.com/alzheimers-disease-biomarkers-and-clinical-trials-insight-2028
With the rapid ageing of world’s population, there is significant rise in the prevalence of dementia associated with Alzheimer disease. The prevalence of Alzheimer disease has become a major social issue as it affects the length and quality of patient’s life and the physiological and economic status of patients and their families. Presently available Alzheimer disease drugs have been unable to halt the progression of Alzheimer disease. Therefore, researchers believed that early diagnosis and prevention of Alzheimer disease is of utmost important to reduce severity and enhance prognosis of the disease.
Therefore, the search for potential clinical biomarkers in Alzheimer disease is one of the hottest areas of research among scientists. The biomarkers identified should be specific, suitable for routine use in clinical practice, and indicate specific stages of the disease. Currently, the most-cited blood and CSF biomarkers for diagnosing Alzheimer disease include the 42-amino acid form of amyloid-beta peptide (Ab1-42), the Ab1-42/Ab1-40 ratio, total and phosphorylated fractions of tau proteins (T-Tau and P-Tau, respectively), neurofilament light chain (NFL) protein, phosphorylated tau at position threonine 181 (P-Tau 181), and 217 (P-Tau217). Apart from this, several ongoing clinical studies are also evaluating other potential biomarkers which can aid in development of diagnostic test or novel targeted therapy for Alzheimer disease.
Recently researchers at Mayo Clinic have identified a new set of markers in blood plasma. This discovery could lead to the development of improved diagnostic tests for Alzheimer’s disease. The study focuses on the RNA molecules which are present in plasma as potential biomarkers for the Alzheimer’s disease in African Americans. The study builds on previous research that identified genetic risk factors for Alzheimer’s disease and established that RNA molecules in blood plasma could potentially be used as biomarkers. This research demonstrates that this discovery could lead to more accurate Alzheimer’s disease screening for everyone, particularly for the people and communities at greatest risk.
Traditionally, the detection of disease-causing pathology associated with Alzheimer’s disease and Vascular Contributions to Cognitive Impairment and Dementia (VCID) is limited to cognitive evaluations and neuroimaging like MRI and PET scans. To mitigate the challenges associated with conventional detection methods, researchers have identified several blood biomarkers, which can be beneficial in the diagnosis of Alzheimer’s and other dementias. The study demonstrated that higher pTau181 and lower beta-amyloid in the blood indicate amyloid plaques of Alzheimer’s in the brain. Further, researchers also found that inflammation proteins in blood were related to damage to blood vessels in the brain. It is suggested that advancements in research regarding biomarkers will allow physicians to detect changes in brain, monitor the disease’s progression, and test the effectiveness of potential treatments.
As per our report findings, the global Alzheimer disease drug market is expected to surpass US$ 5 Billion by 2028 which is mainly attributed to the rise in prevalence of Alzheimer disease. US is expected to hold a dominant share in the global market over the forecast period, owing to rising government initiatives for management of Alzheimer disease, rising awareness among population for early diagnosis of disease, and presence of strong research and development sector. Moreover the rising focus of market players in business strategies such as acquisitions, partnerships, and others are expected to fuel the growth of Alzheimer disease biomarkers market over the forecast period. The major players operating in the market include Pfizer, Acument Pharmaceuticals, Abbott Laboratories, Quanterix Corporation, Diagenic ASA, amongst others.
The report provides in-depth analysis on more than 100 biomarkers which are present in clinical trials across various drugs for Alzheimer disease. The report presents detailed analyses of the key market trends, drivers and opportunities, market size and forecasts, top investment pockets, and competitive landscape. Strategies recorded by the key players are analyzed thoroughly to understand the competitive outlook of the market .
Contact:
Preeti Dureja
Research Partner
Biomarkers Insights
sample@biomarkersinsights.com